Loading clinical trials...
Loading clinical trials...
A Phase I Trial of VS-6766 (RO5126766) (a Dual RAF/MEK Inhibitor) Exploring Intermittent, Oral Dosing Regimens in Patients With Solid Tumours or Multiple Myeloma, With an Expansion to Explore Intermittent Dosing in Combination With Everolimus
Conditions
Interventions
VS-6766
Everolimus
Locations
3
United Kingdom
Royal Marsden NHS Foundation Trust
Sutton, Surrey, United Kingdom
Guy's and St Thomas' Hospital
London, United Kingdom
Gynaecological Unit - Royal Marsden NHS Foundation Trust
London, United Kingdom
Start Date
June 17, 2013
Primary Completion Date
October 15, 2025
Completion Date
October 15, 2025
Last Updated
January 29, 2026
NCT05671510
NCT03563976
NCT06679101
NCT06498635
NCT06257264
NCT03872661
Lead Sponsor
Royal Marsden NHS Foundation Trust
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions